Remedium Bio successfully closes $2.3m expansion seed raise
Remedium Bio announced that the company has raised more than $2.3 million in its expanded round of seed financing. The funds raised will be used to research Remedium’s lead product: a single injection gene therapy that could reverse cartilage loss. This research is being done in collaboration with Tufts University School of Medicine scientists who are researching rheumatic diseases.
Fund, Primo Medical Group, Angel Star Ventures (Apis Health Angels), MicroVentures and Guindy Alumni angels were all involved in the financing. Fund, Primo, Medical Group, Angel Star Ventures Apis Health Angels MicroVentures and Guindy Alumni Angels.
Longevity. Technology: Remedium has a pipeline of therapeutic indications for diabetes, stroke, osteoarthritis and other unmet clinical needs.
Source:
